StockGlow

Connect Biopharma Holdings Limited (CNTB)

Develops an antibody drug to treat severe asthma and COPD flare-ups

$2.08-0.01%Healthcare
Compare CNTB with
StockGlow Score
57
Neutral
BearishBullish
1 year ago+4.0%

The outlook

CNTB is trading near its 52-week lows with analysts overwhelmingly rating it a Strong Buy and setting an average price target around 243% above the current level. The stock sits below both its 50- and 200-day moving averages, suggesting a weak near-term trend despite the bullish analyst sentiment.

What’s behind the score

Analyst consensusStrong Buy — 1.1 avg of 8 analysts
Price trendBelow its 50- & 200-day averages
52-week range33% of the way from its 52-week low to high
Price targetAvg target +243% vs current price

Analyst price target

~12-month · 8 analysts
$7.13average target+242.5% vs now
Now $2.08
Low $4.00High $10.00

Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.

Market cap
$131.0M
52-wk high
$3.82
52-wk low
$1.23
50-day avg
$2.25
200-day avg
$2.40
Trailing P/E
—

Similar stocks

ADAGAdagene Inc.$3.73+5.67%FNCHQFinch Therapeutics Group, Inc.$9.97-0.30%INABIN8bio, Inc.$1.11-6.72%ALGSAligos Therapeutics, Inc.$4.25+4.17%UNCYUnicycive Therapeutics, Inc.$4.94-3.70%

The StockGlow Score is a snapshot of current, observable market data (analyst ratings, price trend, 52-week range) — not a prediction, forecast, or recommendation. Informational only, not investment advice. Data from public sources and may be delayed. How this works·Privacy